Bionano Genomics, Inc. (NASDAQ:BNGO) Short Interest Up 28.2% in October

Bionano Genomics, Inc. (NASDAQ:BNGO) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 9,830,000 shares, an increase of 28.2% from the October 15th total of 7,670,000 shares. Based on an average daily trading volume, of 2,010,000 shares, the short-interest ratio is currently 4.9 days. Approximately 10.3% of the shares of the stock are short sold.

Bionano Genomics Stock Down 3.8 %

Bionano Genomics stock traded down $0.01 during trading hours on Friday, reaching $0.25. The stock had a trading volume of 2,836,577 shares, compared to its average volume of 1,776,913. Bionano Genomics has a 52 week low of $0.24 and a 52 week high of $2.27. The company has a market cap of $21.16 million, a price-to-earnings ratio of -0.05 and a beta of 2.37. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.63 and a quick ratio of 1.11. The business’s 50 day moving average price is $0.36 and its 200-day moving average price is $0.60.

Hedge Funds Weigh In On Bionano Genomics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in Bionano Genomics by 47.3% during the 3rd quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock valued at $401,000 after buying an additional 283,639 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Bionano Genomics in the 3rd quarter worth approximately $46,000. Carret Asset Management LLC grew its position in Bionano Genomics by 89.0% during the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after purchasing an additional 40,055 shares during the last quarter. Armistice Capital LLC acquired a new position in Bionano Genomics during the 2nd quarter valued at approximately $1,138,000. Finally, Cetera Advisors LLC acquired a new stake in shares of Bionano Genomics during the first quarter worth $163,000. 11.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. BTIG Research downgraded Bionano Genomics from a “buy” rating to a “neutral” rating in a research report on Tuesday, September 10th. Scotiabank reaffirmed a “sector perform” rating and set a $1.00 price target (down previously from $6.00) on shares of Bionano Genomics in a research note on Wednesday, August 28th. Finally, LADENBURG THALM/SH SH lowered shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Friday.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.